Product Images Cimerli
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 16 images provide visual information about the product associated with Cimerli NDC 70114-441 by Coherus Biosciences Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Image - cimerli 01
Image - cimerli 02
Image - cimerli 03
Image - cimerli 04
Image - cimerli 05
Figure 1 - cimerli 06
This is a tabular data that depicts the mean change in visual acuity for two different periods (one for AMD-1 and one for AMD-2). There is a comparison between the impact of the two different treatments (Ranibizumab 0.5 mg and Verteporfin PDT) and sham treatment. The change in visual acuity is measured based on the number of letters by which the visual acuity changes. The table shows the data for the two periods and the different treatments administered to the patients.*
Figure 2 - cimerli 07
Figure 3 - cimerli 08
Figure 4 - cimerli 09
This document appears to be a chart or graph displaying the percentage of patients who have received a certain number of injections. The mean number of injections for these patients is 10.3. However, the chart itself is not available in this text.*
Figure 5 - cimerli 10
Figure 6 - cimerli 11
Mean Change in Visual Acuity over a period of months for patients treated with Ranibizumab 0.3 mg (n=125) and Sham (n=127) in a clinical study. The study involved monitoring the changes in visual acuity using a chart for each patient over a period of time. The chart shows the mean changes in visual acuity in both treatment groups over the study period.*
Figure 7 - cimerli 12
Figure 8 - cimerli 13
This is a data table showing percentages of eyes (upper 95% Cl) with either 3-step or 2-step improvement in Year 1 and Year 2. The data is further divided into two categories: eyes with baseline diabetic macular edema (DME) and eyes without baseline DME. There are three values in each row corresponding to the percentage of eyes with either 3-step or 2-step improvement seen in 75%, 50%, and 25% of the instances. There is no clear context to this table to provide further information.*
Figure 9 - cimerli 14
PRINCIPAL DISPLAY PANEL - 0.3 mg Vial Carton - cimerli 15
This is a medication called CIMERLD, also known as ranibizumab-eqrn, which is injected into the eye for the treatment of diabetic macular edema and diabetic retinopathy. Each box contains one single-dose vial and prescribing information. The vial contains 0.3mg of the medication. This product requires a prescription and should only be used for intravitreal administration. NDC 7011444001 is the National Drug Code for this medication.*
PRINCIPAL DISPLAY PANEL - 0.5 mg Vial Carton - cimerli 16
CIMERLD is a medication that comes in a single-dose glass vial of 0.5 mg of the injection ranibizumab-eqrn. It is for intravitreal use and its use is restricted to prescription only. It is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. The carton contains only one single-dose vial of the medication. Prescribing information for CIMERLD is available.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.